Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Garrett Motion Inc. - Common Stock
Here Group Limited - American Depositary Shares
MIRA Pharmaceuticals, Inc. - Common Stock
Primo Water Corporation - Common Stock
R1 RCM Inc. - Common Stock
RAPT Therapeutics, Inc. - Common Stock
Sandbridge Acquisition Corp Cl A
Edit Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Mira Pharmaceuticals, Inc.
MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
November 17, 2026
From
Mira Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
MIRA
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
October 29, 2026
From
Mira Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
MIRA
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
October 22, 2026
From
Mira Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
MIRA
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
September 17, 2026
From
Mira Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
MIRA
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
September 01, 2026
From
Mira Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
MIRA
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
August 06, 2026
From
Mira Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
MIRA
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
July 30, 2026
From
Mira Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
MIRA
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.